Table 2 The association of baseline factors with post-recurrence survival in patients treated with PARPi monotherapy and platinum-based chemotherapy after secondary relapse
| Â | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
Characteristics | HR (95%CI) | p value | HR (95%CI) | p value |
Age (years) | ||||
 ≤49 | 0.70 (0.39-1.25) | 0.223 | -- | -- |
 >49 | Reference |  | -- | -- |
Regions of 3rd line | ||||
 PARPi monotherapy | 0.74 (0.41-1.35) | 0.331 | -- | -- |
 Chemotherapy | Reference |  | -- | -- |
PARPi history | ||||
 Yes | 0.37 (0.19-0.72) | 0.003 | 0.46 (0.23-0.89) | 0.022 |
 No | Reference |  | Reference |  |
 Residual Lesions |  | 0.145 |  |  |
 R0 | Reference |  | Reference | 0.270 |
 R1+R2 | 0.77 (0.39-1.54) | 0.465 | 0.91 (0.46-1.82) | 0.794 |
 Unknown | 0.45 (0.21-1.00) | 0.049 | 0.53 (0.24-1.71) | 0.115 |
BRCA mutation | ||||
 BRCA1 | 1.20 (0.58-2.49) | 0.630 | -- | -- |
 BRCA2 | Reference |  | -- | -- |
Stage at diagnosis | ||||
 I/II | 0.72 (0.26-2.03) | 0.534 | -- | -- |
 III/IV | Reference |  | -- | -- |
NAC-IDS | ||||
 Yes | 0.82 (0.39-1.72) | 0.600 | -- | -- |
 No | Reference |  | -- | -- |
1st PFI (months) | ||||
 ≥12 | 1.23 (0.63-2.37) | 0.546 | -- | -- |
 <12 | Reference |  | -- | -- |
2nd PFI (months) | ||||
 ≥12 | 0.47 (0.23-0.94) | 0.034 | 0.50 (0.24-1.02) | 0.057 |
 <12 | Reference |  | Reference |  |
 CA-125 at secondary recurrence (U/ml) |  | 0.211 | -- | -- |
 ≤70 | Reference |  |  |  |
 >70 | 0.70 (0.35-1.41) | 0.316 | -- | -- |
 Unknown | 0.47 (0.20-1.09) | 0.078 | -- | -- |